Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Status and phase: Unknown; Phase 3

Conditions: Gastric Cancer

Treatments: Drug: apatinib

Study type: Interventional

Funder types: Other

Identifiers

NCT02537171

AHEAD-G303

Details and patient eligibility

About

The study is to evaluate the efficacy of Apatinib in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction.

Full description

The study is to investigate the efficacy of Apatinib as maintenance therapy after first fine treatment in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction through progression-free survival(PFS). Apatinib will be given to patients who have received first-line chemotherapy with an efficacy assessment of stable disease(SD), complete response(CR), or partial response(PR) after 4 cycles. Patients were randomly assigned to 750mg group or 500mg group continually until disease progression or intolerable toxicity or patients withdrawal of consent, and the sample size is 40 individuals.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age≥18 years;

2. Pathologically diagnosed with advanced gastric adenocarcinoma (including gastroesophageal junction) with measurable metastases outside the stomach (≥10mm on spiral CT scan, and meet the criteria of Response Evaluation Criteria in Solid Tumors 1.1);

3. Locally advanced, recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma;

4. Finished first-line chemotherapy (fluorouracil combined with oxaliplatin, cisplatin, paclitaxel or docetaxel) 3 weeks a cycle for 4 cycles, of which the last efficacy assessment is SD, PR or CR. No more than 28 days from the starting day of last cycle of chemotherapy;

5. Eastern Cooperative Oncology Group（ECOG）performance status 0 or 1;

6. Blood routine test and Biochemical tests:

   • Hemoglobin ≥ 80g / L;
   • Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L;
   • Platelet count≥ 90 × 109 / L;
   • Alanine aminotransferase (ALT)and Aspartate aminotransferase (AST) <2.5× upper limit of normal (ULN); liver metastases, if any, the ALT and AST<5 × ULN;
   • Serum total bilirubin≤1.5 × ULN;
   • Serum creatinine≤1.5 × ULN;
   • Serum albumin≥30g/L;

7. Life expectancy more than 3 months;

8. Voluntarily join the study and sign the Informed Consent Form for the study;

9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.

Exclusion criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories;
2. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassⅠ; Ⅰ-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class Ⅰcardiac dysfunction; Patients with positive urinary protein;
3. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
4. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or haematemesis in the past 2 months;primary lesion in stomach with positive fecal occult blood test (+) should be evaluated by endoscopy and other potential massive haemorrhage conditions evaluated by the investigator;
5. Abnormal Coagulation (international normalized ratio>1.5, activated partial thromboplastin time>1.5 UNL), with tendency of bleeding;
6. Associated with central nervous system (CNS) metastases;
7. Pregnant or lactating women;
8. Suffering from other malignancies within 5 years;
9. History of uncontrolled psychotropic drug abuse or mental disorders;
10. Participated in other clinical study within 4 weeks;
11. Prior VEGFR inhibitor treatment,such as sorafenib and sunitinib ;
12. Concomitant disease conditions judged by investigator that may seriously affect subject's safety or affect the study completion;
13. Other cases that the researcher found ineligible

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Apatinib 750mg group

Active Comparator group

Description:

Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).

Treatment:

Drug: apatinib

Apatinib 500mg group

Active Comparator group

Description:

Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.

Treatment:

Drug: apatinib